Limesand Kirsten H, Chibly Alejandro Martinez, Fribley Andrew
Department of Nutritional Sciences, University of Arizona, Tucson, AZ 85721, USA.
Growth Horm IGF Res. 2013 Oct;23(5):135-40. doi: 10.1016/j.ghir.2013.06.001. Epub 2013 Jun 29.
The IGF system has been shown to have either negative or negligible impact on clinical outcomes of tumor development depending on specific tumor sites or stages. This review focuses on the clinical impact of IGF signaling in head and neck cancer, the effects of IGF targeted therapies, and the multi-dimensional role of IRS 1/2 signaling as a potential mechanism in resistance to targeted therapies. Similar to other tumor sites, both negative and positive correlations between levels of IGF-1/IGF-1-R and clinical outcomes in head and neck cancer have been reported. In addition, utilization of IGF targeted therapies has not demonstrated significant clinical benefit; therefore the prognostic impact of the IGF system on head and neck cancer remains uncertain.
根据特定肿瘤部位或阶段,IGF系统对肿瘤发展的临床结果显示出负面或可忽略不计的影响。本综述重点关注IGF信号传导在头颈癌中的临床影响、IGF靶向治疗的效果,以及IRS 1/2信号传导作为靶向治疗耐药潜在机制的多维度作用。与其他肿瘤部位类似,已有报道称IGF-1/IGF-1-R水平与头颈癌临床结果之间存在负相关和正相关。此外,IGF靶向治疗的应用尚未显示出显著的临床益处;因此,IGF系统对头颈癌的预后影响仍不确定。